Zymeworks Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZYME research report →
Companywww.zymeworks.com
Zymeworks Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
- CEO
- Kenneth H. Galbraith
- IPO
- 2017
- Employees
- 299
- HQ
- Middletown, BC, CA
Price Chart
Valuation
- Market Cap
- $1.83B
- P/E
- -18.07
- P/S
- 22.49
- P/B
- 0.01
- EV/EBITDA
- 2026.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 94.42%
- Op Margin
- -140.35%
- Net Margin
- -126.33%
- ROE
- -0.25%
- ROIC
- -0.03%
Growth & Income
- Revenue
- $105.97M · 38.87%
- Net Income
- $-81,130,000 · 33.88%
- EPS
- $-1.08 · 33.33%
- Op Income
- $-92,535,000
- FCF YoY
- 69.48%
Performance & Tape
- 52W High
- $29.75
- 52W Low
- $11.02
- 50D MA
- $25.69
- 200D MA
- $21.73
- Beta
- 1.19
- Avg Volume
- 671.46K
Get TickerSpark's AI analysis on ZYME
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Schneider Paul R | other | 178,000 |
| May 13, 26 | Schneider Paul R | other | 119,000 |
| May 13, 26 | Schneider Paul R | other | 0 |
| Apr 9, 26 | Schayowitz Adam | other | 76,000 |
| Apr 9, 26 | Schayowitz Adam | other | 70,000 |
| Apr 9, 26 | Schayowitz Adam | other | 47,000 |
| Apr 9, 26 | Platshon Scott | other | 76,000 |
| Apr 9, 26 | Platshon Scott | other | 70,000 |
| Apr 9, 26 | Platshon Scott | other | 47,000 |
| Apr 9, 26 | Schayowitz Adam | other | 0 |
Our ZYME Coverage
We haven't published any research on ZYME yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ZYME Report →